Biogen's pricey muscle drug Spinraza too costly for Britain
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder/File Photo Spinraza, which has a U.S. list price… Read More »